A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.

医学 多西紫杉醇 养生 内科学 食管癌 临床终点 新辅助治疗 顺铂 化疗 临床研究阶段 化疗方案 放化疗 肿瘤科 胃肠病学 外科 随机对照试验 癌症 乳腺癌
作者
Ken Kato,Yoshinori Ito,Hiroyuki Daiko,Soji Ozawa,Takashi Ogata,Hiroki Hara,Takashi Kojima,Tetsuya Abe,Takeo Bamba,Masaya Watanabe,Hirofumi Kawakubo,Yuichi Shibuya,Yasuhiro Tsubosa,Naoki Takegawa,Takeshi Kajiwara,Hideo Baba,Masaki Ueno,Ryunosuke Machida,Kenichi Nakamura,Yuko Kitagawa
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (4_suppl): 238-238 被引量:188
标识
DOI:10.1200/jco.2022.40.4_suppl.238
摘要

238 Background: Neoadjuvant treatment is the standard care for locally advanced esophageal squamous cell cancer (ESCC). JCOG1109 (UMIN000009482) compared the doublet and triplet of chemotherapy and chemoradiotherapy as neoadjuvant treatment. Methods: Eligible patients (pts) with ESCC of clinical stage IB, II, III (excluding T4) (UICC 7th) from 44 institutions were randomized 1:1:1 to neoadjuvant CF (cisplatin 80 mg/m 2 on day1 plus 5-FU 800 mg/m 2 on days 1-5 Q3W/2course), DCF (docetaxel 70 mg/m 2 on day 1, cisplatin 70 mg/m 2 on day1, plus 5-FU 750 mg/m 2 on days 1-5 Q3W/3 course), or CF-RT (cisplatin 75 mg/m 2 on day 1 plus 5-FU 1000 mg/m 2 on days 1-4 Q4W/2course, radiation 41.4 Gy/23 fr). Primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), %R0 resection, %objective response by neoadjuvant therapy, %pathological complete response (pCR) and safety. Differences in OS was assessed in the ITT using the stratified log-rank test. The data cutoff date for the analysis was July 20, 2021. Results: Of 601 pts 199 CF, 202 DCF, and 200 CF-RT were enrolled from December 5, 2012 to July 20, 2018, respectively. Among 601 pts, 88.2% were male, median (range) age was 65 (30-75), clinical stage III (nonT4) pts were 62.6%. Median follow-up time (range) was 4.2 years (y) (0-8.5). Median OS in CF, DCF, and CF-RT arm were 4.6 y, not reached (NR), and 6.0y, and 3-year OS was 62.6%, 72.1%, and 68.3%, respectively (stratified log-rank test: p = 0.006 for CF vs. DCF and p = 0.12 for CF vs. CF-RT). By stratified Cox regression analysis for OS, hazard ratios (HR) [95% CI] was 0.68 [0.50–0.92] for CF vs. DCF and 0.84 [0.63–1.12] for CF vs. CF-RT. Median PFS in CF, DCF, and CF-RT arm were 2.7 y, NR, and 5.3 y, and 3-year PFS was 47.7%, 61.8%, and 58.5%, respectively. R0 resection was achieved in 168 (84.4%), 173 (85.6%), and 175 (87.5%), and pCR was 4 (2.1%), 40 (19.8%), and 77 (38.5%), respectively. During neoadjuvant therapy, febrile neutropenia in CF, DCF, and CF-RT arm were 1.0%, 16.3% and 4.7%, and esophagitis (grade>3) were 1.0%, 1.0% and 8.9%, respectively. The treatment-related death was seen in 3 (1.5%), 4 (2.0%), and 2 (1.0%), in CF, DCF, and CF-RT arm, respectively. Conclusions: DCF significantly improved OS over CF as neoadjuvant therapy for locally advanced ESCC, with a manageable toxicity profile. DCF represents a new standard neoadjuvant treatment for ESCC. Clinical trial information: UMIN000009482.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Felix发布了新的文献求助10
2秒前
2秒前
今后的应助被DXL采纳,获得10
2秒前
1997SD完成签到,获得积分10
2秒前
yael发布了新的文献求助30
3秒前
千秋完成签到,获得积分20
4秒前
Hello的应助被xuexue采纳,获得10
4秒前
4秒前
4秒前
4秒前
5秒前
fantasy的应助被表弟慢热手采纳,获得10
6秒前
ttjek发布了新的文献求助10
6秒前
任伟超发布了新的文献求助10
8秒前
Lee发布了新的文献求助10
8秒前
千秋发布了新的文献求助20
8秒前
8秒前
9秒前
名字无法显示完成签到,获得积分10
10秒前
10秒前
纸飞机完成签到,获得积分10
10秒前
轻飏发布了新的文献求助10
11秒前
11秒前
科目三的应助被Hase采纳,获得10
11秒前
饼干不加酵母菌完成签到,获得积分10
12秒前
14秒前
yael完成签到,获得积分10
14秒前
李健的小迷弟的应助被渟柠采纳,获得10
14秒前
15秒前
zhilingZhang发布了新的文献求助10
15秒前
思源的应助被xhj采纳,获得10
17秒前
小蘑菇的应助被超级无敌采纳,获得30
17秒前
鱼游天下完成签到,获得积分10
17秒前
ecoochen发布了新的文献求助10
18秒前
脑洞疼的应助被adai采纳,获得10
18秒前
19秒前
英姑的应助被苹果依凝采纳,获得10
19秒前
上官若男的应助被Trick_Room采纳,获得10
20秒前
小牛发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193348
求助须知:如何正确求助?哪些是违规求助? 9579548
关于积分的说明 21866040
捐赠科研通 7792906
什么是DOI,文献DOI怎么找? 3437242
关于科研通互助平台的介绍 2560702
邀请新用户注册赠送积分活动 2484066